A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

NCT07064486 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the experimental drug BGM0504 in adults with type 2 diabetes in Indonesia.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 477 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2025-07 · est. completion 2026-07

Where 4 sites · Indonesia

What this study is testing ClinicalTrials.gov NCT07064486 ↗

Description as written by the study sponsor.

This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes

Treatments tested

BGM0504 Drug

Administered SC
BGM0504 Drug

Administered SC
Semaglutide Drug

Administered SC

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c)
Sponsor	BrightGene Bio-Medical Technology Co., Ltd.
Conditions studied	Type 2 Diabetes (T2DM)
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07064486 ↗